The Delaware State Investment Board has approved a $30.2 million grant for Merck & Company to potentially build a major factory at the Chestnut Run Innovation and Science Park. This grant, the largest in the past eight years, surpasses the $16.5 million granted to Bloom Energy in 2011. Merck is considering the CRISP site for their new facility, codenamed Project Fast Pitch, which will manufacture drugs under development with an anticipated investment of $900 million. The pharmaceutical giant is known for blockbuster medicines like Keytruda and Gardasil, generating $64.2 billion in sales in 2024. Merck currently has a Delaware facility in Millsboro and is a leading poultry vaccine manufacturer globally. The CRISP developers, MRA Group, have not commented on the plans for Merck’s facility. Merck’s proposed investment includes building costs, engineering fees, utility expenses, and new equipment procurement, with plans to seek $25.5 million in Capex Grants. Demolition is already underway at the CRISP site, where other companies like Prelude Therapeutics and Solenis have established a presence. Stay tuned for updates on this developing story.
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
